Allied Market Research

2024

North America Dendritic Cell Cancer Vaccine Market

North America Dendritic Cell Cancer Vaccine Market Size, Share, Competitive Landscape and Trend Analysis Report by Product Type (CreaVax, Sipuleucel-T (Provenge), Others) and by End User (Pediatrics, Adults): Global Opportunity Analysis and Industry Forecast, 2023-2032

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Dendritic cells (DCs) refer to rare kinds of leukocytes. They are used in therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells. Isolated DCs loaded with tumor antigen ex vivo that are administered as a cellular vaccine are found to induce protective & therapeutic anti-tumor immunity in experimental animals.

An increase in the prevalence of cancer and improvement of technology such as drug innovations regarding cancer drive the market growth. However, stringent regulatory procedures restrain the market. Upsurge in the awareness of cancer and their available therapies in the market, along with an increase in healthcare expenditure are expected to provide opportunities for the market growth.

This report segments the North American dendritic cell cancer vaccine market based on type, end user, and country. Based on type, it is categorized into CreaVax, Sipuleucel-T (Provenge), and others. Based on end user, it is classified into pediatrics and adults. By country, it has been analyzed across the U.S., Canada, and Mexico.

The key players of the dendritic cell cancer vaccine market are 3M Company, Argos Therapeutics, Creagene, Dendreon Corporation, Elios Therapeutics, ImmunoCellular Therapeutics, Merck & Co., Inc., GlaxoSmithKline plc, Northwest Biotherapeutics, Inc., and Tella Incorporation.

Key Benefits

  • The study provides an in-depth analysis of the market with current trends and future estimations to elucidate imminent investment pockets.
  • The report provides information about the current and upcoming trends in the market from 2016 to 2023, which helps determine prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the growth of the market has been provided.
  • Identification of factors that are instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market have been provided.
  • Key market players within the market have been profiled in this report and their strategies thoroughly analyzed, which help understand the competitive outlook of the market.

North America Dendritic Cell Cancer Vaccine Market Key Segments:

By Product Type

  • CreaVax
  • Sipuleucel-T (Provenge)
  • Others

By End User

  • Pediatrics
  • Adults

By Country

  • U.S.
  • Canada
  • Mexico

North America Dendritic Cell Cancer Vaccine Market Report Highlights

Aspects Details
North America Dendritic Cell Cancer Vaccine Market By Product Type
By Product Type
  • CreaVax
  • Sipuleucel-T (Provenge)
  • Others
North America Dendritic Cell Cancer Vaccine Market By End User
By End User
  • Pediatrics
  • Adults
North America Dendritic Cell Cancer Vaccine Market By Region
By Region
  • North America  (U.S., Canada, Mexico)
Key Market Players
Key Market Players

GlaxoSmithKline plc, Elios Therapeutics, Merck & Co., Inc., Dendreon Corporation, 3M Company, ImmunoCellular Therapeutics, Argos Therapeutics, Northwest Biotherapeutics, Inc., Creagene, Tella Incorporation

Loading Table Of Content...

North America Dendritic Cell Cancer Vaccine Market

Global Opportunity Analysis and Industry Forecast, 2023-2032